論文 - 詳細
| RRC ID | 61874 |
|---|---|
| 著者 | Shinmi D, Nakano R, Mitamura K, Suzuki-Imaizumi M, Iwano J, Isoda Y, Enokizono J, Shiraishi Y, Arakawa E, Tomizuka K, Masuda K. |
| タイトル | Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. |
| ジャーナル | Cancer Med |
| Abstract |
Carcinoembryonic antigen (CEA) is a classic tumor-specific antigen that is overexpressed in several cancers, including gastric cancer. Although some anti-CEA antibodies have been tested, to the best of our knowledge, there are currently no clinically approved anti-CEA antibody therapies. Because of this, we have created the novel anti-CEA antibody, 15-1-32, which exhibits stronger binding to membrane-bound CEA on cancer cells than existing anti-CEA antibodies. 15-1-32 also shows poor affinity for soluble CEA; thus, the binding activity of 15-1-32 to membrane-bound CEA is not influenced by soluble CEA. In addition, we constructed a 15-1-32-monomethyl auristatin E conjugate (15-1-32-vcMMAE) to improve the therapeutic efficacy of 15-1-32. 15-1-32-vcMMAE showed enhanced antitumor activity against gastric cancer cell lines. Unlike with existing anti-CEA antibody therapies, antitumor activity of 15-1-32-vcMMAE was retained in the presence of high concentrations of soluble CEA. |
| 巻・号 | 6(4) |
| ページ | 798-808 |
| 公開日 | 2017-4-1 |
| DOI | 10.1002/cam4.1003 |
| PMID | 28211613 |
| PMC | PMC5387159 |
| MeSH | Animals Antibodies, Monoclonal / administration & dosage* Antibodies, Monoclonal / chemistry Antibodies, Monoclonal / pharmacology Carcinoembryonic Antigen / immunology* Cell Line, Tumor Cell Proliferation / drug effects Cell Survival / drug effects Humans Mice Oligopeptides / chemistry* Stomach Neoplasms / drug therapy* |
| IF | 3.491 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 6 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 3.0 |
| リソース情報 | |
| ヒト・動物細胞 | L929 |